BioSpace News Archive

Business

Agilent to Announce First-Quarter Fiscal Year 2024 Financial Results Feb. 27

Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27.

January 25, 2024
·
1 min read
Biotech Beach

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Renovaro Biosciences Inc. announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.

January 25, 2024
·
1 min read
Drug Development

Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial

Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial.

January 25, 2024
·
2 min read
Confluent Announces Significant Investment in ATI Nitinol Melt ExpansionConfluent Becomes ATI’s Fulfillment Partner for Medical Nitinol

Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure.

January 25, 2024
·
3 min read
Biotech Bay

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator.

January 25, 2024
·
5 min read
FDA

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

The U.S. Food and Drug Administration has approved Dupixent® for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis.

January 25, 2024
·
16 min read
FDA

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

January 25, 2024
·
22 min read
Drug Development

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA ® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU.

January 25, 2024
·
11 min read
Business

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

CVRx, Inc. (“CVRx”) today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.

January 25, 2024
·
16 min read
Biotech Bay

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been dosed with UX701 across the three dose-escalation cohorts in Stage 1 of its pivotal Phase 1/2/3 Cyprus2+ study.

January 25, 2024
·
6 min read